{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:00:30Z","timestamp":1772726430647,"version":"3.50.1"},"reference-count":53,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/20523211.2024.2372089","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:01:09Z","timestamp":1722970869000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Sales and regulatory status of fixed dose combination psychotropic drugs in India: a retrospective longitudinal study"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5239-8829","authenticated-orcid":false,"given":"Paul","family":"Bogowicz","sequence":"first","affiliation":[{"name":"Newcastle University","place":["Newcastle upon Tyne, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-9915","authenticated-orcid":false,"given":"Aashna","family":"Mehta","sequence":"additional","affiliation":[{"name":"Public Health Foundation of India","place":["Gurugram, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0574-992X","authenticated-orcid":false,"given":"Shruti","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Public Health Foundation of India","place":["Gurugram, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2085-0304","authenticated-orcid":false,"given":"Petra","family":"Brhlikova","sequence":"additional","affiliation":[{"name":"Newcastle University","place":["Newcastle upon Tyne, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-2878","authenticated-orcid":false,"given":"Peter","family":"Roderick","sequence":"additional","affiliation":[{"name":"Newcastle University","place":["Newcastle upon Tyne, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-9754","authenticated-orcid":false,"given":"Patricia","family":"McGettigan","sequence":"additional","affiliation":[{"name":"Queen Mary University of London","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3081-2929","authenticated-orcid":false,"given":"Habib Hasan","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Qatar University","place":["Doha, Qatar"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4521","authenticated-orcid":false,"given":"Aditya Narain","family":"Sharma","sequence":"additional","affiliation":[{"name":"Newcastle University","place":["Newcastle upon Tyne, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7388-3110","authenticated-orcid":false,"given":"Allyson M.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Newcastle University","place":["Newcastle upon Tyne, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"AIOCD Pharmasofttech AWACS Pvt Ltd. (2011). PharmaTrac. Retrieved March 4 2024 from https:\/\/aiocdawacs.com\/."},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.224474"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_554_18"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-023-00644-y"},{"key":"e_1_3_6_6_1","unstructured":"Central Drugs Standard Control Organization (2022a). List of approved new drugs. Retrieved March 18 2022 from https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Approval_new\/Approved-New-Drugs\/."},{"key":"e_1_3_6_7_1","unstructured":"Central Drugs Standard Control Organization (2022b). List of banned drugs. Retrieved May 9 2022 from https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs."},{"key":"e_1_3_6_8_1","unstructured":"Central Drugs Standard Control Organization (2022c). New drugs approved by CDSCO. Retrieved March 18 2022 from https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs."},{"key":"e_1_3_6_9_1","unstructured":"Drugs Consultative Committee (1978). Minutes of the 20th meeting of the Drugs Consultative Committee held at New Delhi on the 4th & 5th July 1978. Retrieved July 8 2022 from https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/20thDCCmeeting.pdf."},{"key":"e_1_3_6_10_1","unstructured":"Drugs Controller General (India) (2013). Letter to all state\/UTs drugs controllers. Subject: Approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from office of DCG(I). Retrieved June 24 2022 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=Mjcz."},{"key":"e_1_3_6_11_1","unstructured":"Drugs Controller General (India) (2016a). Notice 01 Sep 2016. Subject: Examination for safety and efficacy of fixed dose combinations (FDCs) licensed for manufacture for sale in the country without due approval from office of DCG (I)-regarding. Retrieved February 20 2024 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NTIz."},{"key":"e_1_3_6_12_1","unstructured":"Drugs Controller General (India) (2016b). Notice 17 Jun 2016. Subject: Examination for safety and efficacy of fixed dose combinations (FDCs) licensed for manufacture for sale in the country without due approval from office of DCG (I)-regarding. Retrieved June 9 2023 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NTM1."},{"key":"e_1_3_6_13_1","unstructured":"Drugs Controller General (India) (2017a). Notice 01 Mar 2017. Subject: Examination for safety and efficacy of fixed dose combinations (FDCs) licensed for manufacture for sale in the country without due approval from office of DCG (I)-regarding. Retrieved February 20 2024 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NDg2."},{"key":"e_1_3_6_14_1","unstructured":"Drugs Controller General (India) (2017b). Notice 05 Jun 2017. Subject: Examination for safety and efficacy of fixed dose combinations (FDCs) licensed for manufacture for sale in the country without due approval from office of DCG(I)-regarding. Retrieved July 8 2022 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NDcx."},{"key":"e_1_3_6_15_1","unstructured":"Drugs Controller General (India) (2019). Letter to manufacturing associations and others. Subject: Procedure to be followed for subsequent applicants in respect of FDCs falling under category \u2018d\u2019 as per Prof. Kokate Committee report (i.e. FDCs which require generation of data). Retrieved July 8 2022 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NDQ2MA==."},{"key":"e_1_3_6_16_1","unstructured":"Drugs Controller General (India) (2020). Procedure to be followed for subsequent applicant in respect of FDCs declared as rational by Prof. Kokate Committee and approved by DCG(I) (Tech. Rep.). Central Drugs Standard Control Organization. Retrieved July 1 2024 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NjcxNQ==."},{"key":"e_1_3_6_17_1","unstructured":"Drugs Controller General (India) (2021a). Letter to all state\/UT drugs controller. Subject: Procedure to be followed for regularisation of 19 FDCs (fixed dose combinations) out of 294 FDCs which require further generation of data which were licensed to manufacture and market by state licensing authority (SLA) without prior approval from DCG(I) -regarding. Retrieved June 9 2023 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NzYxMA."},{"key":"e_1_3_6_18_1","unstructured":"Drugs Controller General (India) (2021b). Procedure to be followed for subsequent applicant in respect of FDCs declared as rational by Prof. Kokate Committee and approved by DCG(I) (Tech. Rep.). Central Drugs Standard Control Organization. Retrieved July 1 2024 from https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NzYwNQ==."},{"key":"e_1_3_6_19_1","unstructured":"Drugs Technical Advisory Board (2018). Minutes of the 68th meeting of Drugs Technical Advisory Board: agenda no S-8; annexures A to G. (via Right to Information request dated 23 December 2017)."},{"key":"e_1_3_6_20_1","unstructured":"European Medicines Agency (2022). Medicines. Retrieved May 30 2022 from https:\/\/www.ema.europa.eu\/en\/medicines\/field_ema_web_categories%253Aname_field\/Human)."},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114541016"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.v16.1"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.224475"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_570_18"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196975"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196973"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_603_23"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_556_18"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196972"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7020017"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196978"},{"key":"e_1_3_6_32_1","unstructured":"High Level Expert Group on Universal Health Coverage (2011). High level expert group report on universal health coverage for India (Tech. Rep.). Planning Commission of India. Retrieved September 28 2023 from https:\/\/phfi.org\/wp-content\/uploads\/2018\/05\/UHC-ExecSummary.pdf."},{"key":"e_1_3_6_33_1","unstructured":"Indian Drug Manufacturers' Association (2014). Annual report 2013-14 (Tech. Rep.). Retrieved from https:\/\/idma-assn.org\/pdf\/idma-annual-report-2013-14.pdf."},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196976"},{"key":"e_1_3_6_35_1","unstructured":"Kokate Committee (2015a). Submission of report by expert committee constituted for examination of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from office of DCG(I) [1st report] (Tech. Rep.). Central Drugs Standard Control Organization."},{"key":"e_1_3_6_36_1","unstructured":"Kokate Committee (2015b). Submission of report by expert committee in respect of FDCs categorized under category \u2018a\u2019 for manufacture for sale in the country without due approval from office of DCG (I) [2nd report] (Tech. Rep.). Central Drugs Standard Control Organization."},{"key":"e_1_3_6_37_1","unstructured":"Kokate Committee (2016a). Submission of report by expert committee constituted for examination of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from office of DCG(I) [3rd report] (Tech. Rep.). Central Drugs Standard Control Organization."},{"key":"e_1_3_6_38_1","unstructured":"Kokate Committee (2016b). Submission of report by expert committee constituted for examination of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from office of DCG(I) [4th report] (Tech. Rep.). Central Drugs Standard Control Organization."},{"key":"e_1_3_6_39_1","unstructured":"Kshirsagar Committee (2018). Submission of report by sub-committee constituted by DTAB for examination of cases of banning of 344 FDCs + 05 FDCs prohibited vide SO No 705(E) to 1048(E) dated 10.03.2016 and SO No 1851(E) to 1855(E) dated 08.06.2017 (Tech. Rep.). Drugs Technical Advisory Board."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001826"},{"key":"e_1_3_6_41_1","unstructured":"Medicines and Healthcare Products Regulatory Agency (2022). MHRA products. Retrieved May 13 2022 from https:\/\/products.mhra.gov.uk"},{"key":"e_1_3_6_42_1","unstructured":"Ministry of Health & Family Welfare (2015). National list of essential medicines 2015 (Tech. Rep.). Retrieved from https:\/\/www.nhp.gov.in\/NHPfiles\/NLEM%2C%202015.pdf."},{"key":"e_1_3_6_43_1","unstructured":"Ministry of Health & Family Welfare (n.d.). The Gazette of India. Retrieved March 4 2024 from https:\/\/egazette.gov.in\/\/."},{"key":"e_1_3_6_44_1","unstructured":"Mishra S. & Gupta V. (2022). Chlorpromazine + trihexyphenidyl + trifluoperazine. Retrieved August 19 2022 from https:\/\/www.1mg.com\/generics\/chlorpromazine-trihexyphenidyl-trifluoperazine-401017."},{"key":"e_1_3_6_45_1","unstructured":"National Health Accounts Technical Secretariat (2021). National health accounts estimates for India 2017\u20132018 (Tech. Rep.). Ministry of Health & Family Welfare. Retrieved June 20 2022 from https:\/\/nhsrcindia.org\/sites\/default\/files\/2021-11\/National%20Health%20Accounts-%202017-18.pdf."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.224477"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.v21.11"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001400"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.196974"},{"key":"e_1_3_6_50_1","volume-title":"Healing the pharmacy of the world","author":"Sharma K","year":"2021","unstructured":"Sharma, K (2021). Healing the pharmacy of the world (1st ed.). Notion Press.","edition":"1"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.224476"},{"key":"e_1_3_6_52_1","unstructured":"US Food & Drug Administration (2022). Drugs@FDA: FDA-approved drugs. Retrieved May 30 2022 from https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"e_1_3_6_53_1","unstructured":"Veerramani S. (2014). Letter to SL Verma Secretary to the Government of India. Subject: Fixed dose combinations (FDCs). Retrieved August 20 2022 from http:\/\/www.idma-assn.org\/pdf\/25-07-2014_Letter_to_Shri_Lov_Verma_Health_Secretary_on_FDCs.pdf."},{"key":"e_1_3_6_54_1","unstructured":"Vendoti D. (2018). Decoding the ban on irrational fixed-dose combination drugs in India (Tech. Rep.). Observer Research Foundation. Retrieved August 22 2022 from https:\/\/www.orfonline.org\/research\/decoding-the-ban-on-irrational-fixed-dose-combination-drugs-in-india-45835\/#_edn7."}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2024.2372089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:59:01Z","timestamp":1772722741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2024.2372089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/20523211.2024.2372089"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2024.2372089","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2372089"}}